The Board of Directors collaborates to provide strategic clarity, direction, and policy objectives for DIA. The Board of Directors and its Standing Committees ensure DIA meets the requirements of our members in the content of our programs, research, and financial decisions.
Board membership is voluntary, and DIA does not compensate Directors or members of Advisory Councils for their contributions.
Joseph C. Scheeren
Chair of DIA Board
Chair of Executive Committee
Dr. Joseph Scheeren has served in executive positions for global regulatory affairs, global and Asia development, consumer care, and R&D for Bayer Pharmaceuticals, Bayer Healthcare, and Bayer AG. Before Bayer, Dr. Scheeren led regulatory affairs and clinical development for Servier, worldwide regulatory affairs for Serono and global regulatory affairs for Roussel UCLAF. He has served on Advisory Boards for the Center for Innovation in Regulatory Science, the Regulatory Affairs track at Yale University, the Center of Regulatory Excellence Singapore, the R&D-based Pharmaceutical Association in China, and the China Core Research and Development Committee. Dr. Scheeren is a nominated adjunct Professor of Regulatory Affairs at Peking University.
John A. (Jay) Roberts
Immediate Past Chair
Chair of Governance Committee
Jay Roberts, MBA, is President and Chief Executive Officer of Cancer Genetics, Inc., a leader in enabling precision medicine in oncology, where he previously served as Chief Operating Officer and Executive Vice President of Finance. Mr. Roberts also served as Chief Financial Officer for VirMedica, Inc.; as Chief Financial Officer and Treasurer for InfoLogix, Inc., a publicly-traded healthcare-centric mobile software and solutions provider acquired by Stanley Healthcare with Mr. Roberts leading the transaction; and as Chairman of the Board of Directors for AdvantEdge Healthcare Solutions Private Limited. He formerly held senior executive roles with MEDecision, Inc., HealthOnline, Inc., and the Center for Health Information.
Rebecca A. Vermeulen
Rebecca Vermeulen, RPh, brings a variety of experiences to her role as Customer Strategy and Patient Partnership for Global Medical Affairs at Roche. She has served in numerous functions including Medical Affairs, Clinical Research, Sales, Medical Communications, Medical Science Liaisons, Patient Partnership, Digital Health, and Six Sigma, in her 26 years of healthcare industry experience, and has been responsible for creating global standards for information exchange with healthcare professionals and patients. Rebecca is currently Vice-Chair of the DIA Board of Directors, Vice-Chair of the Healthcare Businesswomen’s Association Corporate Board of Directors, and serves on the Patient Focused Medicine Development Advisory Committee.
Jeffrey S. Payne
Chair of Finance Committee
Jeffrey Payne is Chief Financial Officer of Katabat, a leading customer experience management solutions company serving the consumer credit industry. Prior to Katabat, Mr. Payne was Treasurer and Senior Vice President of Finance at Biocoat, Inc., and Chief Financial Officer at Picwell Inc., a healthcare IT company. He was CFO for Clinical Ink, an eClinical company providing electronic case report forms and patient retention and engagement; and CFO for CRF Health, an international provider of eCOA solutions. During his tenure, CRF Health became the leading provider of eCOA solutions and Mr. Payne oversaw its successful sale to a London-based private equity firm. A CPA and CGMA, Mr. Payne began his career as an auditor for Arthur Andersen.
Barbara Lopez Kunz
Global Chief Executive
Barbara Lopez Kunz, MS, is responsible for the leadership and oversight of DIA global operations, implementing strategies that focus on driving thought leadership and innovation in therapeutic development to improve the health of people worldwide. Ms. Lopez Kunz previously served as President of Health and Life Sciences at Battelle, one of the world’s largest, most respected research and development organizations. She has also served as Senior Vice President/General Manager for Thermo Fisher Scientific’s Biosciences Business and on the inaugural board of the Childhood League School. She holds 14 patents, earned her Masters Degree in Polymer Science from the University of Akron, and is certified in INSEAD’s International Executive program.
Andrzej Czarnecki, MD, PhD, is the Director and deputy Qualified Person for Pharmacovigilance at Eli Lilly and Company, where he uses his scientific expertise to contribute to scientific solutions within the company and in the pharmaceutical medicine regulatory field. Dr. Czarnecki served on the Development, Programme, and Organising Committees, and is a Fellow of the International Society for Pharmaceutical Engineering, and is also a Fellow of Faculty of Pharmaceutical Medicine. Dr. Czarnecki has also served as Professor of Pharmcoepidemiology at several European universities, and has worked as a consultant for such public bodies as the European Commission, the WHO, and to several governments in Eastern and Western Europe.
Angelika Joos, MPharm, is responsible for Regulatory Policy issues within MSD's Global Regulatory Affairs and Clinical Safety department. This role includes identifying regulatory policy priorities that align with MSD’s business priorities, leading cross-functional networks to define policy positions, and informing MSD’s regulatory strategy development. Angelika represents MSD in various Committees of the European Federation of Pharmaceutical Manufacturers and Associations, EuropaBio, and the European Confederation of Pharmaceutical Entrepreneurs; she is also involved in international policy activities as the MSD delegate in the IFPMA Regulatory Science Committee, and the BIO and the PhRMA international Committees.
Judith Ng-Cashin, MD, serves as Chief Medical Officer at AOBiome Therapeutics, leading end-to-end asset development strategy and medical governance. Dr. Ng-Cashin previously served as Chief Scientific Officer and led the Safety & Pharmacovigilance business unit for Syneos Health. Before Syneos, she spent nearly a decade in R&D for a top five pharmaceutical company spanning early assets to marketed products, global development, and franchise/portfolio strategy/prioritization. Dr. Ng-Cashin earned her MD from Rush Medical College, trained in Internal Medicine at the University of Chicago, and received infectious diseases and hematology fellowship training (and subsequently served on the clinical faculty) at the University of North Carolina.
Chair of Audit Committee
Michael Romano is a Partner and leader of the Life Sciences Industry practice group for RSM US LLP; he is also a Partner in RSM’s Technology and Management Consulting practice, and leads RSM’s Finance and Accounting Outsourcing group. Michael has more than 25 years of diverse experience in both the life sciences industry and as an audit and business consultant, and has orchestrated successful financial and operational turnarounds, restructured and reorganized businesses, and successfully executed growth strategies in the life sciences industry. He also served as Vice President and General Manager of a global medical publisher offering health information products and services to the pharmaceutical, biotech, and medical device markets.
Michael Rosenblatt, MD, Chief Medical Officer of Flagship Pioneering, has advanced academic and biopharmaceutical research and development throughout his career. He was previously Chief Medical Officer for Merck, after serving as Dean of Tufts Medical School. Formerly, he was Ebert Professor of Molecular Medicine and Minot Professor at Harvard. He served as President of Beth Israel Deaconess Medical Center and as Director of the Harvard-MIT Division of Health Sciences & Technology. He is on the board of several biotech companies, and on the Harvard Medical School Board of Fellows and research advisory committees of the Massachusetts General, Brigham and Women’s, and Children’s Hospitals. He earned his MD from Harvard Medical School.
Jonathan Gary Sheldon
Jonathan Sheldon, PhD, is Senior Vice President and member of the Executive Committee at QIAGEN, leading the Bioinformatics Business Unit and contributing to the QIAGEN governing body responsible for defining corporate strategy. Dr. Sheldon previously served as Global Vice President Healthcare at Oracle, and has held various CXO positions in software companies serving both the life science and healthcare sectors. Prior to the software industry, Dr. Sheldon was Head of Bioinformatics for five years at Roche (UK) Pharmaceuticals. Dr. Sheldon has been served on various advisory groups and boards including as a Director of the tranSMART Foundation, and earned his PhD in Molecular Cell Biology from the University of Cambridge.
Dr. Takahashi is currently Vice President and Director of Japan Development, GlaxoSmithKline K.K. He graduated from Hokkaido University School of Medicine in 1981, and received his PhD in Medical Science in 1986. He served as Research Assistant Professor of Medicine at Vanderbilt University from 1990 to 1992, and joined Merck Research Laboratories in 1992 and served as Vice President, Merck Research Laboratories from 2003 to 2008. After retiring from Merck, he served as a President & CEO of LOTUS Pharmaceutical Co. Ltd, a bio-venture company before joining GSK.
Lingshi Tan, PhD, is Chairman and Chief Executive Officer of dMed Co. Ltd., a China-based contract research organization. Prior to founding dMed, Dr. Tan was Pfizer’s Vice President of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co., Ltd. He previously served as Pfizer’s Head of Global Biometrics for Japan, Asia, Africa, Mideast, and Latin America. Dr. Tan is a council member of Peking University’s Pharmaceutical Information and Engineering Research Center, and the inaugural Chair of the Research and Development Heads Working Group of Research & Development-based Pharmaceutical Association Committee in China. He earned his PhD in Biostatistics from the University of Pittsburgh.
Cynthia L. Verst
Cynthia L. Verst, PharmD, MS, is President of Design and Delivery Innovation for Research and Development Solutions at IQVIA, responsible for accelerating growth through innovative solutions powered by rich data assets, advanced predictive analytics, integrated technology capabilities, and deep domain expertise to develop actionable insights that drive better clinical research outcomes. Dr. Verst has been named one of the Top Women in Biotech by FierceBiotech, and is the 2018 Vice Chairman of the Association of Clinical Research Organizations. Dr. Verst earned her PharmD and Bachelor’s degree in Pharmacy from the University of Cincinnati, and her Master’s degree in Structural and Cellular Biology from the University of Illinois.